A research report featured on the cover of the September 2009 print issue of The FASEB Journal (http://www.fasebj.org) describes how Australian scientists developed a new gene therapy vector that uses the same machinery that viruses use to transport their cargo into our cells. As a result of this achievement, therapeutic DNA can be transferred to a cell’s nucleus far more efficiently than in the past, raising hopes for more effective treatment of genetic disorders and some types of cancers.
“Through the use of proteins that mimic key functions of viruses for the packaging and transport of therapeutic DNA, we hope to improve the efficiency, and above all, the specificity of human gene therapy,” said David Jans, from the Nuclear Signaling Laboratory at Monash University in Victoria, Australia and one of the researchers involved in the work. “Following the creation of efficient, specific and safe DNA delivery vectors, the challenges in human gene therapy will be able to move on from questions of delivery to actual clinical application.”
In short, a gene therapy vector is used to deliver a therapeutic gene or a portion of DNA into a cell nucleus similar to how a syringe is used to inject medicines. To create the new gene therapy vector, Jans and colleagues used pieces of different genes to create a protein called a “modular DNA carrier,” which can be produced by bacteria. This protein carries therapeutic DNA and delivers it to a cell’s nucleus, where it reprograms a cell to function properly. In the laboratory, these carrier proteins were combined with therapeutic DNA and attached to cell membrane receptors and the nuclear import machinery of target cells. In turn, the packaged DNA moved into the cell through the cytoplasm and into the nucleus.
“Effective gene therapy is clearly the best way to treat heritable diseases. It’s also an approach to other diseases where the environment or infection messes up our genes.” said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. “The Australians have worked out how viruses identify our nuclear ZIP-code, and have delivered therapeutic genes to the same address. This work opens up a new era of pharmaceutical development.”
Receive monthly highlights from The FASEB Journal by e-mail. Sign up at http://www.faseb.org/fasebjournalreaders.htm. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB). The journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information. FASEB comprises 22 nonprofit societies with more than 80,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB advances biological science through collaborative advocacy for research policies that promote scientific progress and education and lead to improvements in human health.
Details: Dominic J. Glover, Su May Ng, Adam Mechler, Lisandra L. Martin, and David A. Jans. Multifunctional protein nanocarriers for targeted nuclear gene delivery in nondividing cells. FASEB J. 2009 23: 2996-3006. http://www.fasebj.org/cgi/content/abstract/23/9/2996
